CN112142851A - 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 - Google Patents
一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 Download PDFInfo
- Publication number
- CN112142851A CN112142851A CN201910577765.4A CN201910577765A CN112142851A CN 112142851 A CN112142851 A CN 112142851A CN 201910577765 A CN201910577765 A CN 201910577765A CN 112142851 A CN112142851 A CN 112142851A
- Authority
- CN
- China
- Prior art keywords
- protein
- fusion protein
- subunit fusion
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 43
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 43
- 241000711798 Rabies lyssavirus Species 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 108091006027 G proteins Proteins 0.000 claims abstract description 49
- 102000030782 GTP binding Human genes 0.000 claims abstract description 49
- 108091000058 GTP-Binding Proteins 0.000 claims abstract description 49
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 239000013612 plasmid Substances 0.000 claims abstract description 16
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims abstract description 7
- 238000010367 cloning Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 82
- 229960005486 vaccine Drugs 0.000 claims description 18
- 206010037742 Rabies Diseases 0.000 claims description 17
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 101710091045 Envelope protein Proteins 0.000 claims description 7
- 101710188315 Protein X Proteins 0.000 claims description 7
- 102100021696 Syncytin-1 Human genes 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 23
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000001179 sorption measurement Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000013638 trimer Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101710194807 Protective antigen Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- SXTAYKAGBXMACB-DPVSGNNYSA-N L-methionine sulfoximine Chemical compound CS(=N)(=O)CC[C@H](N)C(O)=O SXTAYKAGBXMACB-DPVSGNNYSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000012879 subculture medium Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910577765.4A CN112142851B (zh) | 2019-06-28 | 2019-06-28 | 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910577765.4A CN112142851B (zh) | 2019-06-28 | 2019-06-28 | 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112142851A true CN112142851A (zh) | 2020-12-29 |
CN112142851B CN112142851B (zh) | 2023-05-05 |
Family
ID=73869566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910577765.4A Active CN112142851B (zh) | 2019-06-28 | 2019-06-28 | 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112142851B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113252893A (zh) * | 2021-06-23 | 2021-08-13 | 北京市动物疫病预防控制中心 | 一种应用狂犬病毒g蛋白快速定量检测狂犬病毒抗体的方法、g蛋白的编码基因及试纸 |
CN115785281A (zh) * | 2022-09-27 | 2023-03-14 | 兴盟生物医药(苏州)有限公司 | 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用 |
CN116621949A (zh) * | 2023-04-25 | 2023-08-22 | 华南生物医药研究院 | 一种增加狂犬病毒g蛋白分泌表达的方法及应用 |
CN117298263A (zh) * | 2023-09-27 | 2023-12-29 | 成都迈科康生物科技有限公司 | 一种重组狂犬病疫苗及其制备方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040030098A1 (en) * | 2002-03-29 | 2004-02-12 | Lee Liana M. | Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, BGS5G and BGS5I |
CN101550193A (zh) * | 2008-11-04 | 2009-10-07 | 江苏大学 | 一种新型IZ-shGITRL融合蛋白及其制备方法和应用 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN102898526A (zh) * | 2011-07-28 | 2013-01-30 | 山东先声麦得津生物制药有限公司 | 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN104628851A (zh) * | 2015-02-12 | 2015-05-20 | 长春百克生物科技股份公司 | 一种抗狂犬病毒的基因工程抗体、其制备方法和应用 |
CN107287224A (zh) * | 2016-03-30 | 2017-10-24 | 深圳市北科生物科技有限公司 | 分泌trail的间充质干细胞及其治疗脑瘤的用途 |
CN107973841A (zh) * | 2016-12-23 | 2018-05-01 | 浙江海隆生物科技有限公司 | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 |
CN109627294A (zh) * | 2018-12-29 | 2019-04-16 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
-
2019
- 2019-06-28 CN CN201910577765.4A patent/CN112142851B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040030098A1 (en) * | 2002-03-29 | 2004-02-12 | Lee Liana M. | Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, BGS5G and BGS5I |
CN101550193A (zh) * | 2008-11-04 | 2009-10-07 | 江苏大学 | 一种新型IZ-shGITRL融合蛋白及其制备方法和应用 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN102898526A (zh) * | 2011-07-28 | 2013-01-30 | 山东先声麦得津生物制药有限公司 | 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN104628851A (zh) * | 2015-02-12 | 2015-05-20 | 长春百克生物科技股份公司 | 一种抗狂犬病毒的基因工程抗体、其制备方法和应用 |
CN107287224A (zh) * | 2016-03-30 | 2017-10-24 | 深圳市北科生物科技有限公司 | 分泌trail的间充质干细胞及其治疗脑瘤的用途 |
CN107973841A (zh) * | 2016-12-23 | 2018-05-01 | 浙江海隆生物科技有限公司 | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 |
CN109627294A (zh) * | 2018-12-29 | 2019-04-16 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
Non-Patent Citations (4)
Title |
---|
HUALONG XI: "Engineering of a novel zipFv using leucine zipper motif against rabies virus glycoprotein G with improved protection potency in vivo", 《IMMUNOLOGY LETTERS》, 4 April 2017 (2017-04-04), pages 9 - 14, XP085033878, DOI: 10.1016/j.imlet.2017.04.001 * |
NCBI: "glycoprotein [Rabies lyssavirus]:GenBank: ADJ29911.1", 《NCBI GENBANK》, 30 June 2010 (2010-06-30), pages 1 * |
ZHUANG LI等: "A novel variable antibody fragment dimerized by leucine zippers with enhanced neutralizing potency against rabies virus G protein compared to its corresponding single-chain variable antibody fragment", 《MOLECULAR IMMUNOLOGY》, 29 August 2015 (2015-08-29), pages 168 - 175 * |
李鑫等: "表达猪H1N1亚型流感病毒三聚体HA的重组慢病毒包装", 《中国兽医学报》, no. 12, 15 December 2012 (2012-12-15), pages 1828 - 1831 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113252893A (zh) * | 2021-06-23 | 2021-08-13 | 北京市动物疫病预防控制中心 | 一种应用狂犬病毒g蛋白快速定量检测狂犬病毒抗体的方法、g蛋白的编码基因及试纸 |
CN115785281A (zh) * | 2022-09-27 | 2023-03-14 | 兴盟生物医药(苏州)有限公司 | 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用 |
CN116621949A (zh) * | 2023-04-25 | 2023-08-22 | 华南生物医药研究院 | 一种增加狂犬病毒g蛋白分泌表达的方法及应用 |
CN116621949B (zh) * | 2023-04-25 | 2024-01-30 | 华南生物医药研究院 | 一种增加狂犬病毒g蛋白分泌表达的方法及应用 |
CN117298263A (zh) * | 2023-09-27 | 2023-12-29 | 成都迈科康生物科技有限公司 | 一种重组狂犬病疫苗及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112142851B (zh) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10925959B2 (en) | Porcine epidemic diarrhea virus S protein and subunit vaccine thereof as well as method for preparing subunit vaccine and application thereof | |
CN112142851A (zh) | 一种狂犬病毒表面的亚单位融合蛋白tG及其制备方法和应用 | |
CN111393531B (zh) | 一种亚单位融合蛋白CD2V-Fc及其制备方法和应用 | |
CN111217918A (zh) | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 | |
CN111234036B (zh) | 非洲猪瘟病毒p72融合蛋白及其制备方法和应用 | |
CN110317278B (zh) | Svv和fmdv的融合蛋白及其编码基因、表达载体、细胞系、工程菌和疫苗与应用 | |
CN111471089B (zh) | 一种重组的非洲猪瘟病毒cd2v亚单位蛋白及其制备方法和应用 | |
CN108159409A (zh) | 一种猪圆环病毒3型Cap蛋白疫苗及其制备方法和应用 | |
CN107973841B (zh) | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 | |
CN110981968B (zh) | 含有狂犬病病毒g蛋白的融合蛋白及其制备方法、应用和疫苗 | |
CN112390863B (zh) | 改造的新冠病毒Spike蛋白胞外结构域及其应用 | |
CN113512096A (zh) | 一种鲈鱼弹状病毒重组g2蛋白及其应用 | |
CN111607001A (zh) | 一种重组的非洲猪瘟病毒p72亚单位可溶性融合蛋白及其制备方法和应用 | |
CN110041411A (zh) | 稳定的非典型猪瘟病毒亚单位蛋白及其疫苗和制备方法和应用 | |
CN115025212A (zh) | 用于预防猪繁殖与呼吸综合征的mRNA疫苗及制备方法 | |
CN112142827B (zh) | 一种猪伪狂犬病毒的gB亚单位重组蛋白及其制备方法和应用 | |
CN112430273A (zh) | 一种狂犬病毒表面的亚单位融合蛋白mG及其制备方法和应用 | |
WO2018188639A1 (zh) | 猪流行性腹泻病毒s蛋白及其亚单位疫苗及其制备方法和应用 | |
KR102332725B1 (ko) | 오량체 기반 재조합 단백질 백신 플랫폼 및 이를 발현하는 시스템 | |
CN111607000A (zh) | 一种重组的非洲猪瘟病毒p30亚单位可溶性融合蛋白及其制备方法和应用 | |
CN111378017A (zh) | 小反刍兽疫病毒的亚单位f蛋白及其制备方法和应用 | |
CN116655751A (zh) | 重组猪瘟e2蛋白及其亚单位疫苗的制备方法和应用 | |
CN113735943A (zh) | 一种重组的非洲猪瘟病毒p72亚单位蛋白和制备方法及其应用 | |
CN107325188A (zh) | 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用 | |
CN111378016B (zh) | 小反刍兽疫病毒的亚单位h蛋白及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Applicant after: NOVO BIOTECH Corp. Address before: 312000 5th floor, building 2, science and innovation center, 398 mahuan Road, Binhai New Town, Shaoxing City, Zhejiang Province Applicant before: NOVO BIOTECH Corp. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee after: Zhejiang Hailong Biotechnology Co.,Ltd. Country or region after: China Address before: 312366 No. 1, Baichuan Road, Binhai New Area, Shaoxing City, Zhejiang Province Patentee before: NOVO BIOTECH Corp. Country or region before: China |